Innovent Biologics and Pfizer Enter Global Strategic Collaboration to Accelerate Development of Innovative Oncology Medicines
Stocks in this Quantisnow insightHealth Care
Historical context for PFE
Across the 26 sessions after earlier PFE headlines, the stock closed higher 10 times and lower 15 times, with a median move of 0.8% in either direction. This shows timing only: many things move a stock in a session, and these figures do not show that any headline caused a move.
| Session | Earlier headline | PFE | SPY |
|---|---|---|---|
| May 27, 2026 | Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference | +1.4% | -0.0% |
| May 20, 2026 | Pfizer Advances Pivotal Pediatric Pneumococcal Vaccine Program Following Strong Positive Phase 2 Results | +0.5% | +1.0% |
| May 18, 2026 | Astellas to Present Data on Long-Term Outcomes and Clinical Use of Its Portfolio Across Disease Stages at ASCO 2026 | +0.0% | -0.1% |
| May 13, 2026 | European Commission Approves Pfizer's HYMPAVZI for the Treatment of Adults and Adolescents with Hemophilia A or B With Inhibitors | +0.3% | +0.6% |
| May 5, 2026 | Pfizer Reports Strong First-Quarter Results And Reaffirms 2026 Guidance | +0.6% | +0.8% |
| Apr 29, 2026 | Pfizer's ELREXFIO Significantly Improves Progression-Free Survival for Double-Class Exposed Patients with Relapsed or Refractory Multiple Myeloma | -0.8% | -0.0% |
Quantisnow market dataNYSE
PFE
Pfizer Inc.
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
Get push alerts for PFE
Full PFE profile on Quantisnow Follow PFE and get a push notification the moment its next story breaks.